Optimal | Warning | Failure | |
Baseline | NA | High risk or CCA/Ph+, major route | NA |
Three months | BCR-ABL1 ≤10 percent and/or Ph+ ≤35 percent | BCR-ABL1 >10 percent and/or Ph+ 36 to 95 percent | Non-CHR and/or Ph+ >95 percent |
Six months | BCR-ABL1 <1 percent and/or Ph+ 0 | BCR-ABL1 1 to 10 percent and/or Ph+ 1 to 35 percent | BCR-ABL1 >10 percent and/or Ph+ >35 percent |
12 months | BCR-ABL1 ≤0.1 percent | BCR-ABL1 >0.1 to 1 percent | BCR-ABL1 >1 percent and/or Ph+ >0 |
Then, and at any time | BCR-ABL1 ≤0.1 percent | CCA/Ph– (–7, or 7q–) | Loss of CHR Loss of CCyR Confirmed loss of MMR* Mutations CCA/Ph+ |
Do you want to add Medilib to your home screen?